For people with Graves' disease who relapse and take methimazole a second time, staying on the drug longer—more than 3.5 years—makes it more likely their disease will stay in remission after stopping, even if their antibody levels are already normal.
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
A systematic review of RCTs would determine whether extending MMI duration beyond 24–36 months causally increases remission rates in relapsed Graves' disease, independent of TRAb levels.
A systematic review and meta-analysis of all randomized trials comparing extended MMI (>5 years) versus standard-duration MMI (24–36 months) in patients with relapsed Graves' disease, with TRAb negativity as an inclusion criterion. Primary outcome: remission rate at 2 years post-discontinuation.
An RCT would determine whether assigning patients to 5 years versus 3 years of MMI after TRAb negativity causally increases remission rates.
A multicenter, double-blind RCT of 200 adults with relapsed Graves' disease and confirmed TRAb negativity after 24 months of MMI, randomized to continue 5 mg/day MMI for 3 years versus 5 years. Primary outcome: euthyroidism without relapse at 2 years after discontinuation. Secondary outcomes: TRAb reversion, quality of life, and adverse events.
A prospective cohort with standardized treatment duration could determine whether longer MMI exposure independently predicts remission after adjusting for TRAb kinetics and baseline severity.
A prospective cohort of 250 adults with relapsed Graves' disease who achieve TRAb negativity after 24 months of MMI, followed for 5 years with quarterly thyroid function and TRAb testing. Patients are stratified by planned treatment duration (3 vs. 5 years). Multivariate analysis adjusts for age, TRAb decline rate, and TPOAb levels.
A case-control study could identify whether treatment duration is a stronger predictor of remission than TRAb levels or other biomarkers.
A case-control study comparing 60 patients who achieved sustained remission (>2 years) after a second MMI course with 60 who relapsed within 1 year, matched for age, sex, and baseline TRAb. Exposure variables: total MMI duration, TRAb decline slope, and TPOAb levels. Odds ratios calculated for predictors.
A cross-sectional survey could estimate the average treatment duration among patients currently in remission after a second MMI course, but cannot determine causality.
A cross-sectional survey of 400 adults with relapsed Graves' disease currently in remission after stopping MMI, asking for total duration of second course and time since discontinuation.